At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 200 enrolled
Drug / intervention
ALK-001 oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular Degeneration
In Brief
A Phase 3 clinical trial evaluating ALK-001 oral capsule and Placebo oral capsule for Geographic Atrophy and 3 related conditions. Completed, enrolled 200 participants across 24 sites.
Detailed Summary
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMay 2019
Primary CompletionJul 2023
Study CompletionJun 2024
TodayJul 2026
First PostedFeb 19, 2019
Enrollment StartMay 7, 2019
Primary CompletionJul 25, 2023
Study CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 7.4 years ago
Interventions
ALK-001 oral capsuledrug
Daily administration for 24 months
Placebo oral capsuledrug
Daily administration for 24 months